ArticleOncology letters2025

Neutrophil‑to‑lymphocyte ratio and risk of disease progression in patients with nivolumab‑treated unresectable or recurrent gastric cancer.

Hirokatsu Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.